Introduction

Psoriasis is a chronic inflammatory skin condition known to affect about 1%-3% of the global population. Psoriasis can be a serious burden to the patients, having deleterious effect on their physical, social and mental wellbeing. Systemic therapies consisting of methotrexate, cyclosporine, acitretin, PUVA, etc. used in moderate to severe psoriasis, are associated with end organ toxicity with long term use.

Areas covered

Role of Itolizumab, an anti CD6 biologic in regulation of lymphocyte development, selection, activation and differentiation in the set-up of psoriasis. We performed a literature review by searching online databases including PubMed and Google Scholar.

Expert opinion

There is emerging evidence to implicate CD6 and its ligands in the pathogenesis and potentially the treatment of inflammatory and autoimmune diseases, like psoriasis and multiple sclerosis. Its potential advantage over anti TNF biologics in predisposing to lesser risk of tuberculosis and other serious systemic infections or adverse effects makes it a potential valuable asset in the armamentarium of anti-psoriasis drugs.

中文翻译：

---

用于治疗牛皮癣的抗CD6单克隆抗体。

介绍

牛皮癣是一种慢性炎症性皮肤病，已知会影响全球人口的1％-3％。牛皮癣可能给患者带来沉重负担，对他们的身体，社会和心理健康产生有害影响。中度至重度牛皮癣使用的由甲氨蝶呤，环孢菌素，阿维A，维甲酸组成的全身疗法与终端器官毒性相关，需要长期使用。

覆盖区域

Itolizumab（一种抗CD6生物制剂）在牛皮癣患者体内调节淋巴细胞发育，选择，激活和分化中的作用。我们通过搜索在线数据库（包括PubMed和Google Scholar）进行了文献综述。

专家意见

越来越多的证据表明，CD6及其配体可能与炎症和自身免疫性疾病（如牛皮癣和多发性硬化症）的发病机理以及潜在的治疗手段有关。与抗TNF生物制剂相比，它在降低结核病和其他严重全身感染或不良反应的风险方面具有潜在优势，使其成为抗银屑病药物装备中的潜在宝贵资产。